The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines

By        

International Journal of Oncology, Vol. 45, Iss. 1, 2014-01 ,pp. : 393-400

Spandidos Publications

Access to resources Recommend Favorite

Cross-Resistance Studies of Isogenic Drug-Resistant Breast Tumor Cell Lines Support Recent Clinical Evidence Suggesting that Sensitivity to Paclitaxel may be Strongly Compromised by Prior Doxorubicin Exposure

By Guo Baoqing  

Breast Cancer Research and Treatment, Vol. 85, Iss. 1, 2004-05 ,pp. : 31-51

Springer Publishing Company

Access to resources Recommend Favorite

Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 6, 2004-11 ,pp. : 523-534

Bentham Science Publishers

Access to resources Recommend Favorite

High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study

By                    

Oncology Letters, Vol. 3, Iss. 1, 2012-01 ,pp. : 61-65

Spandidos Publications

Access to resources Recommend Favorite

Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

By Bergman A.M.   Giaccone G.   van Moorsel C.J.A.   Mauritz R.   Noordhuis P.   Pinedo H.M.   Peters G.J.  

European Journal of Cancer, Vol. 36, Iss. 15, 2000-10 ,pp. : 1974-1983

Elsevier

Access to resources Recommend Favorite